MX2018011300A - Composiciones y metodos para el tratamiento de la presbicia. - Google Patents

Composiciones y metodos para el tratamiento de la presbicia.

Info

Publication number
MX2018011300A
MX2018011300A MX2018011300A MX2018011300A MX2018011300A MX 2018011300 A MX2018011300 A MX 2018011300A MX 2018011300 A MX2018011300 A MX 2018011300A MX 2018011300 A MX2018011300 A MX 2018011300A MX 2018011300 A MX2018011300 A MX 2018011300A
Authority
MX
Mexico
Prior art keywords
compositions
presbyopia
treatment
methods
preservative
Prior art date
Application number
MX2018011300A
Other languages
English (en)
Inventor
Horn Gerald
NORDAN Lee
Original Assignee
Presbyopia Therapies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/073,139 external-priority patent/US9833441B2/en
Priority claimed from US15/073,089 external-priority patent/US9844537B2/en
Priority claimed from US15/235,431 external-priority patent/US10052313B2/en
Application filed by Presbyopia Therapies Llc filed Critical Presbyopia Therapies Llc
Publication of MX2018011300A publication Critical patent/MX2018011300A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La invencion proporciona composiciones y metodos para el tratamiento de la presbicia y otros defectos de la vision; las composiciones comprenden preferiblemente aceclidina y un poliol y/o un agente cicloplejico; las composiciones contienen opcionalmente un agente tensoactivo, un potenciador de la viscosidad, un modificador de la osmolaridad y un conservador.
MX2018011300A 2016-03-17 2017-03-08 Composiciones y metodos para el tratamiento de la presbicia. MX2018011300A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15/073,139 US9833441B2 (en) 2013-08-28 2016-03-17 Compositions and methods for the treatment of presbyopia
US15/073,089 US9844537B2 (en) 2013-08-28 2016-03-17 Compositions and methods for the treatment of presbyopia
US15/235,431 US10052313B2 (en) 2013-08-28 2016-08-12 Compositions and methods for the treatment of presbyopia
PCT/US2017/021244 WO2017160548A1 (en) 2016-03-17 2017-03-08 Compositions and methods for the treatment of presbyopia

Publications (1)

Publication Number Publication Date
MX2018011300A true MX2018011300A (es) 2019-02-18

Family

ID=59852351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011300A MX2018011300A (es) 2016-03-17 2017-03-08 Composiciones y metodos para el tratamiento de la presbicia.

Country Status (6)

Country Link
EP (1) EP3429584A4 (es)
JP (1) JP2019508472A (es)
CN (1) CN108883102A (es)
CA (1) CA3017755A1 (es)
MX (1) MX2018011300A (es)
WO (1) WO2017160548A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147535A2 (en) * 2018-01-24 2019-08-01 Eye Therapies, Llc Methods for improving vision
US20190321334A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
US20220273557A1 (en) * 2019-07-26 2022-09-01 Allergan Sales, Llc Compositions and methods for treatment of presbyopia
JP2023548336A (ja) * 2020-11-02 2023-11-16 ヴィーサス セラピューティクス インコーポレイテッド 医薬品中の分解性化合物
CN114588156A (zh) * 2022-04-22 2022-06-07 温州医科大学附属眼视光医院 一种眼用制剂及其在治疗老花眼中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120758A (en) * 1998-07-16 2000-09-19 Shaklee Corporation Preservative system for topically applied products
US10052313B2 (en) * 2013-08-28 2018-08-21 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9314427B2 (en) * 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
JP2017501224A (ja) * 2013-12-18 2017-01-12 ジー・エヌ・ティー・エル・エル・シー 緑内障の治療用組成物及び方法

Also Published As

Publication number Publication date
JP2019508472A (ja) 2019-03-28
EP3429584A1 (en) 2019-01-23
CN108883102A (zh) 2018-11-23
EP3429584A4 (en) 2019-11-13
CA3017755A1 (en) 2017-09-21
WO2017160548A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
MX2018011300A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
MX2020002922A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2020005772A (es) Composiciones que comprenden cepas bacterianas.
MX2021003819A (es) Moduladores de alfa-1 antitripsina.
MX2020009455A (es) Composiciones que comprenden cepas bacterianas.
MX2018010484A (es) Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
GB2537078A (en) Settable compositions and uses thereof
MY186271A (en) Ophthalmic compositions and methods of use therefor
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2017007852A (es) Formulaciones de acido hipocloroso y metodos para tratar afecciones de la piel.
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
PH12017500870A1 (en) Polymer composition comprising basic additive, process and articles comprising said polymer composition
PH12017501864A1 (en) Compositions and methods for treating autism
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
EP3274548A4 (en) METHODS AND COMPOSITIONS FOR INJECTING ACTIVE SOLUTIONS OF HIGH CONCENTRATION AND / OR HIGH VISCOSITY
MD3630136T2 (ro) Compoziții care cuprind tulpini bacteriene
MX2017005183A (es) Metodo de tratamiento para antibrote de tuberculos con cantidad reducida de cipc.
GB2543723A (en) Polyphenol compositions
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same